2015
DOI: 10.1517/17425255.2015.1046433
|View full text |Cite|
|
Sign up to set email alerts
|

Neonatal medicines research: challenges and opportunities

Abstract: Challenges relating to neonatal medicine research can largely be overcome. Tailored tools and legal initiatives, combined with clever trial design will result in more robust information on neonatal pharmacotherapy. This necessitates collaborative efforts between clinical researchers, sponsors, regulatory authorities, and last but not least patient representatives and society.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 12 publications
(9 citation statements)
references
References 87 publications
(123 reference statements)
0
9
0
Order By: Relevance
“…Hence, only a brief overview will be provided to illustrate its impact. Body water content is proportionally larger, body fat content is proportionally smaller in neonates in comparison to adults (impact on distribution), and liver and kidney function are not fully developed at birth, which is an important factor considering metabolism and elimination of many drugs [3,4]. Generally, the maturation of DMEs does not follow a single, uniform pattern, but displays iso-enzyme-specific maturation.…”
Section: Introductionmentioning
confidence: 99%
“…Hence, only a brief overview will be provided to illustrate its impact. Body water content is proportionally larger, body fat content is proportionally smaller in neonates in comparison to adults (impact on distribution), and liver and kidney function are not fully developed at birth, which is an important factor considering metabolism and elimination of many drugs [3,4]. Generally, the maturation of DMEs does not follow a single, uniform pattern, but displays iso-enzyme-specific maturation.…”
Section: Introductionmentioning
confidence: 99%
“…In addition to the complex and unique aspects of perinatal-neonatal pharmacokinetics [ 37 , 39 ], pharmacodynamic changes associated with development may present a challenge for pharmacotherapeutic interventions. Therefore, drug targets (including ion channels) that are present and functional in adults may be absent or may have not yet reached a functional mature state, which considerably undermines their pharmacological value during the fetal and neonatal period [ 39 40 ].…”
Section: Discussionmentioning
confidence: 99%
“…However, few of these refer to neonates, which remain one of the last therapeutic orphans [19]. Design and reporting of RCTs in neonates seem to be of poor quality without any substantial improvement during the past years, as identified by Kaguelidou et al in a systematic review of RCTs of antibiotics for neonatal infections [20].…”
Section: High Variability In Antibiotic Dosingmentioning
confidence: 99%